Abstract
Summary
LPI (LP Information)' newest research report, the “Orphan Drugs for Adults Industry Forecast” looks at past sales and reviews total world Orphan Drugs for Adults sales in 2022, providing a comprehensive analysis by region and market sector of projected Orphan Drugs for Adults sales for 2023 through 2029. With Orphan Drugs for Adults sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orphan Drugs for Adults industry.
This Insight Report provides a comprehensive analysis of the global Orphan Drugs for Adults landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orphan Drugs for Adults portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Orphan Drugs for Adults market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orphan Drugs for Adults and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orphan Drugs for Adults.
The global Orphan Drugs for Adults market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Orphan Drugs for Adults is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Orphan Drugs for Adults is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Orphan Drugs for Adults is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Orphan Drugs for Adults players cover Abbvie Inc., Orpharma, Amgen Inc., Recordati SpA, Novartis, Celgene, Amryt Pharma Plc., Johnson & Johnson and GSK Plc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Orphan Drugs for Adults market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Segmentation by application
Hospital Pharmacies
Retail pharmacies
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbvie Inc.
Orpharma
Amgen Inc.
Recordati SpA
Novartis
Celgene
Amryt Pharma Plc.
Johnson & Johnson
GSK Plc.
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals
This Insight Report provides a comprehensive analysis of the global Orphan Drugs for Adults landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orphan Drugs for Adults portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Orphan Drugs for Adults market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orphan Drugs for Adults and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orphan Drugs for Adults.
The global Orphan Drugs for Adults market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Orphan Drugs for Adults is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Orphan Drugs for Adults is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Orphan Drugs for Adults is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Orphan Drugs for Adults players cover Abbvie Inc., Orpharma, Amgen Inc., Recordati SpA, Novartis, Celgene, Amryt Pharma Plc., Johnson & Johnson and GSK Plc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Orphan Drugs for Adults market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others
Segmentation by application
Hospital Pharmacies
Retail pharmacies
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbvie Inc.
Orpharma
Amgen Inc.
Recordati SpA
Novartis
Celgene
Amryt Pharma Plc.
Johnson & Johnson
GSK Plc.
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Orphan Drugs for Adults Market Size 2018-2029
2.1.2 Orphan Drugs for Adults Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Orphan Drugs for Adults Segment by Type
2.2.1 Oncology Drugs
2.2.2 Gastrointestinal Drugs
2.2.3 Neurology Drugs
2.2.4 Cardio-vascular Drugs
2.2.5 Others
2.3 Orphan Drugs for Adults Market Size by Type
2.3.1 Orphan Drugs for Adults Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Orphan Drugs for Adults Market Size Market Share by Type (2018-2023)
2.4 Orphan Drugs for Adults Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail pharmacies
2.4.3 Others
2.5 Orphan Drugs for Adults Market Size by Application
2.5.1 Orphan Drugs for Adults Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Orphan Drugs for Adults Market Size Market Share by Application (2018-2023)
3 Orphan Drugs for Adults Market Size by Player
3.1 Orphan Drugs for Adults Market Size Market Share by Players
3.1.1 Global Orphan Drugs for Adults Revenue by Players (2018-2023)
3.1.2 Global Orphan Drugs for Adults Revenue Market Share by Players (2018-2023)
3.2 Global Orphan Drugs for Adults Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Orphan Drugs for Adults by Regions
4.1 Orphan Drugs for Adults Market Size by Regions (2018-2023)
4.2 Americas Orphan Drugs for Adults Market Size Growth (2018-2023)
4.3 APAC Orphan Drugs for Adults Market Size Growth (2018-2023)
4.4 Europe Orphan Drugs for Adults Market Size Growth (2018-2023)
4.5 Middle East & Africa Orphan Drugs for Adults Market Size Growth (2018-2023)
5 Americas
5.1 Americas Orphan Drugs for Adults Market Size by Country (2018-2023)
5.2 Americas Orphan Drugs for Adults Market Size by Type (2018-2023)
5.3 Americas Orphan Drugs for Adults Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Orphan Drugs for Adults Market Size by Region (2018-2023)
6.2 APAC Orphan Drugs for Adults Market Size by Type (2018-2023)
6.3 APAC Orphan Drugs for Adults Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Orphan Drugs for Adults by Country (2018-2023)
7.2 Europe Orphan Drugs for Adults Market Size by Type (2018-2023)
7.3 Europe Orphan Drugs for Adults Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Orphan Drugs for Adults by Region (2018-2023)
8.2 Middle East & Africa Orphan Drugs for Adults Market Size by Type (2018-2023)
8.3 Middle East & Africa Orphan Drugs for Adults Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Orphan Drugs for Adults Market Forecast
10.1 Global Orphan Drugs for Adults Forecast by Regions (2024-2029)
10.1.1 Global Orphan Drugs for Adults Forecast by Regions (2024-2029)
10.1.2 Americas Orphan Drugs for Adults Forecast
10.1.3 APAC Orphan Drugs for Adults Forecast
10.1.4 Europe Orphan Drugs for Adults Forecast
10.1.5 Middle East & Africa Orphan Drugs for Adults Forecast
10.2 Americas Orphan Drugs for Adults Forecast by Country (2024-2029)
10.2.1 United States Orphan Drugs for Adults Market Forecast
10.2.2 Canada Orphan Drugs for Adults Market Forecast
10.2.3 Mexico Orphan Drugs for Adults Market Forecast
10.2.4 Brazil Orphan Drugs for Adults Market Forecast
10.3 APAC Orphan Drugs for Adults Forecast by Region (2024-2029)
10.3.1 China Orphan Drugs for Adults Market Forecast
10.3.2 Japan Orphan Drugs for Adults Market Forecast
10.3.3 Korea Orphan Drugs for Adults Market Forecast
10.3.4 Southeast Asia Orphan Drugs for Adults Market Forecast
10.3.5 India Orphan Drugs for Adults Market Forecast
10.3.6 Australia Orphan Drugs for Adults Market Forecast
10.4 Europe Orphan Drugs for Adults Forecast by Country (2024-2029)
10.4.1 Germany Orphan Drugs for Adults Market Forecast
10.4.2 France Orphan Drugs for Adults Market Forecast
10.4.3 UK Orphan Drugs for Adults Market Forecast
10.4.4 Italy Orphan Drugs for Adults Market Forecast
10.4.5 Russia Orphan Drugs for Adults Market Forecast
10.5 Middle East & Africa Orphan Drugs for Adults Forecast by Region (2024-2029)
10.5.1 Egypt Orphan Drugs for Adults Market Forecast
10.5.2 South Africa Orphan Drugs for Adults Market Forecast
10.5.3 Israel Orphan Drugs for Adults Market Forecast
10.5.4 Turkey Orphan Drugs for Adults Market Forecast
10.5.5 GCC Countries Orphan Drugs for Adults Market Forecast
10.6 Global Orphan Drugs for Adults Forecast by Type (2024-2029)
10.7 Global Orphan Drugs for Adults Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Abbvie Inc.
11.1.1 Abbvie Inc. Company Information
11.1.2 Abbvie Inc. Orphan Drugs for Adults Product Offered
11.1.3 Abbvie Inc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Abbvie Inc. Main Business Overview
11.1.5 Abbvie Inc. Latest Developments
11.2 Orpharma
11.2.1 Orpharma Company Information
11.2.2 Orpharma Orphan Drugs for Adults Product Offered
11.2.3 Orpharma Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Orpharma Main Business Overview
11.2.5 Orpharma Latest Developments
11.3 Amgen Inc.
11.3.1 Amgen Inc. Company Information
11.3.2 Amgen Inc. Orphan Drugs for Adults Product Offered
11.3.3 Amgen Inc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Amgen Inc. Main Business Overview
11.3.5 Amgen Inc. Latest Developments
11.4 Recordati SpA
11.4.1 Recordati SpA Company Information
11.4.2 Recordati SpA Orphan Drugs for Adults Product Offered
11.4.3 Recordati SpA Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Recordati SpA Main Business Overview
11.4.5 Recordati SpA Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Orphan Drugs for Adults Product Offered
11.5.3 Novartis Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
11.6 Celgene
11.6.1 Celgene Company Information
11.6.2 Celgene Orphan Drugs for Adults Product Offered
11.6.3 Celgene Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Celgene Main Business Overview
11.6.5 Celgene Latest Developments
11.7 Amryt Pharma Plc.
11.7.1 Amryt Pharma Plc. Company Information
11.7.2 Amryt Pharma Plc. Orphan Drugs for Adults Product Offered
11.7.3 Amryt Pharma Plc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Amryt Pharma Plc. Main Business Overview
11.7.5 Amryt Pharma Plc. Latest Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Information
11.8.2 Johnson & Johnson Orphan Drugs for Adults Product Offered
11.8.3 Johnson & Johnson Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Johnson & Johnson Main Business Overview
11.8.5 Johnson & Johnson Latest Developments
11.9 GSK Plc.
11.9.1 GSK Plc. Company Information
11.9.2 GSK Plc. Orphan Drugs for Adults Product Offered
11.9.3 GSK Plc. Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 GSK Plc. Main Business Overview
11.9.5 GSK Plc. Latest Developments
11.10 Bristol-Myers Squibb Company
11.10.1 Bristol-Myers Squibb Company Company Information
11.10.2 Bristol-Myers Squibb Company Orphan Drugs for Adults Product Offered
11.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Bristol-Myers Squibb Company Main Business Overview
11.10.5 Bristol-Myers Squibb Company Latest Developments
11.11 Roche Holding
11.11.1 Roche Holding Company Information
11.11.2 Roche Holding Orphan Drugs for Adults Product Offered
11.11.3 Roche Holding Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Roche Holding Main Business Overview
11.11.5 Roche Holding Latest Developments
11.12 Sanofi
11.12.1 Sanofi Company Information
11.12.2 Sanofi Orphan Drugs for Adults Product Offered
11.12.3 Sanofi Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Sanofi Main Business Overview
11.12.5 Sanofi Latest Developments
11.13 Takeda
11.13.1 Takeda Company Information
11.13.2 Takeda Orphan Drugs for Adults Product Offered
11.13.3 Takeda Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Takeda Main Business Overview
11.13.5 Takeda Latest Developments
11.14 Pfizer
11.14.1 Pfizer Company Information
11.14.2 Pfizer Orphan Drugs for Adults Product Offered
11.14.3 Pfizer Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Pfizer Main Business Overview
11.14.5 Pfizer Latest Developments
11.15 Vertex Pharmaceuticals
11.15.1 Vertex Pharmaceuticals Company Information
11.15.2 Vertex Pharmaceuticals Orphan Drugs for Adults Product Offered
11.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Vertex Pharmaceuticals Main Business Overview
11.15.5 Vertex Pharmaceuticals Latest Developments
12 Research Findings and Conclusion